title: Determining PTEN functional status by network component deduced transcription factor activities.
abstract: PTEN-controlled PI3K-AKT-mTOR pathway represents one of the most deregulated signaling pathways in human cancers. With many small molecule inhibitors that target PI3K-AKT-mTOR pathway being exploited clinically, sensitive and reliable ways of stratifying patients according to their PTEN functional status and determining treatment outcomes are urgently needed. Heterogeneous loss of PTEN is commonly associated with human cancers and yet PTEN can also be regulated on epigenetic, transcriptional or post-translational levels, which makes the use of simple protein or gene expression-based analyses in determining PTEN status less accurate. In this study, we used network component analysis to identify 20 transcription factors (TFs) whose activities deduced from their target gene expressions were immediately altered upon the re-expression of PTEN in a PTEN-inducible system. Interestingly, PTEN controls the activities (TFA) rather than the expression levels of majority of these TFs and these PTEN-controlled TFAs are substantially altered in prostate cancer mouse models. Importantly, the activities of these TFs can be used to predict PTEN status in human prostate, breast and brain tumor samples with enhanced reliability when compared to straightforward IHC-based or expression-based analysis. Furthermore, our analysis indicates that unique sets of PTEN-controlled TFAs significantly contribute to specific tumor types. Together, our findings reveal that TFAs may be used as "signatures" for predicting PTEN functional status and elucidate the transcriptional architectures underlying human cancers caused by PTEN loss.
authors.affiliation: Department of Molecular and Medical Pharmacology, University of California Los Angeles, Los Angeles, California, United States of America.
authors.forename: Linh M
authors.initials: LM
authors.lastname: Tran
authors.forename: Chun-Ju
authors.initials: CJ
authors.lastname: Chang
authors.forename: Seema
authors.initials: S
authors.lastname: Plaisier
authors.forename: Shumin
authors.initials: S
authors.lastname: Wu
authors.forename: Julie
authors.initials: J
authors.lastname: Dang
authors.forename: Paul S
authors.initials: PS
authors.lastname: Mischel
authors.forename: James C
authors.initials: JC
authors.lastname: Liao
authors.forename: Thomas G
authors.initials: TG
authors.lastname: Graeber
authors.forename: Hong
authors.initials: H
authors.lastname: Wu
mesh_terms: D000818:Animals; D053263:Gene Regulatory Networks; D006801:Humans; D051379:Mice; D009369:Neoplasms / Q000737:chemistry / Q000209:etiology / Q000473:pathology; D051059:PTEN Phosphohydrolase / Q000032:analysis / Q000502:physiology*; D019869:Phosphatidylinositol 3-Kinases / Q000378:metabolism; D051057:Proto-Oncogene Proteins c-akt / Q000378:metabolism; D015398:Signal Transduction; D058570:TOR Serine-Threonine Kinases / Q000378:metabolism; D014157:Transcription Factors / Q000235:genetics / Q000378:metabolism*
chemical_list: D051059:PTEN Phosphohydrolase; D019869:Phosphatidylinositol 3-Kinases; D051057:Proto-Oncogene Proteins c-akt; D058570:TOR Serine-Threonine Kinases; D014157:Transcription Factors; C546842:MTOR protein, human; C494929:PTEN protein, human